10-Q · May 15, 2026
Cocrystal Pharma reported Q1 2026 with a net loss of $2.30M, slightly improved from a loss of $2.30M in Q1 2025. Total revenue remained at $0, marking a continuation of its pre-revenue status, although the company…
Earnings analysis · 10-Q
COCP earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted Form 10-Q text does not include the financial statements or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be assessed from the available filing content.…
Read full summary
The extracted Form 10-Q text does not include the financial statements or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be assessed from the available filing content. Management reported effective disclosure controls as of June 30, 2026 and no material changes in internal controls or legal proceedings. No financial guidance was provided, and Item 1.A risk factors was marked not applicable to smaller reporting companies.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remain effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, under Exchange Act Rules 13a-15(e) and 15d-15(e).
-
No material control changes
The company reported no material changes in internal control over financial reporting during the quarter ended June 30, 2026.
-
No new material legal proceedings
No material changes were reported to the legal-proceedings disclosures from the March 31, 2026 Form 10-Q during the reporting period.
What to watch
-
Inherent internal-control limitations
The filing states that internal controls have inherent limitations and may not prevent or detect misstatements; future evaluations may be affected by changing conditions or deteriorating compliance. The disclosure references Rules 13a-15(e) and 15d-15(e).
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text. The filing does not discuss an updated financial outlook.
Earlier filings 4
10-K · March 31, 2026
Cocrystal Pharma is a clinical-stage antiviral drug developer advancing multiple programs: CDI-988 (oral pan-viral protease inhibitor) entered a Phase 1b human challenge study in February 2026, CC-42344 (PB2 influenza…
10-Q · August 14, 2024
Cocrystal reported a Q2 net loss of $5,343,000 (EPS -$0.53), widening from -$4,166,000 (-$0.41) year-over-year; six-month net loss was $9,299,000. Operating cash outflow remains large at $8,202,000 for the six months…
10-Q · November 13, 2023
Cocrystal Pharma reported a Q3 net loss of $4,165,000 (EPS $(0.41)), an improvement from Q3 2022 EPS $(0.70). Cash and restricted cash totaled $29.8 million at September 30, 2023 after raising $4.0 million in April…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.